Glooko logo

Glooko Blog

Category: News

Helping Combat Clinician Burnout through EHR Integrations

Glooko EHR Integrations

Mark Clements, MD, PhD, Chief Medical and Strategy Officer, Glooko

At Glooko, we empower healthcare providers with the tools and insights they need to make informed decisions quickly and easily to improve the health outcomes of their patients living with diabetes.

With nearly half of physicians reporting at least one burnout symptom in a recent study from the American Medical Association, it’s critical we make diabetes data management simpler to not overburden those providing care.

That’s why the Glooko platform integrates with leading electronic health record (EHR) systems in the U.S., including Epic, Oracle Health, MEDITECH, Greenway Health, eClinicalWorks, NextGen, and AthenaHealth, making our diabetes management platform seamlessly and securely available within this critical healthcare technology and eliminating the need to platform switch.

Why EHR Integrations Matter

Glooko EHR Integrations

Diabetes care is complex, and healthcare providers face the challenge of managing patient data across multiple systems. In an era where time is precious and clinicians are already spending much of their time on administrative tasks, clinicians need timely access to the most relevant health data without the inefficiencies of navigating multiple data platforms.

By integrating Glooko into EHRs, we streamline how healthcare providers access diabetes data, enabling them to provide the highest quality care. Our integrations provide clinicians and care teams with immediate access to comprehensive data from more than 200 diabetes and health monitoring devices used by their patients, eliminating the need for additional logins and manual data entry by people living with diabetes each day.

EHR integrations not only optimize existing systems, but they also have the potential to enhance clinical decision-making by giving clinicians the full picture of a person’s health. It empowers them to make faster, more informed treatment decisions. That’s why health systems spend $2.5 million to $1.2 billion on EHR integrations each year. They’re powerful and their care teams can reap the benefits of reduced documentation burden.

How It Works

By leveraging SMART on FHIR technology and HL7, standard interoperability frameworks, Glooko integrates with existing EHR systems at hospitals and health systems. Healthcare providers can then access patients’ timely glucose data, medication logs, activity levels, food intake, and much more without leaving the EHR.

The integrations support healthcare systems by offering a single, unified view of a person’s diabetes information, all while ensuring secure, HIPAA-compliant data exchange. The technology is designed to streamline workflows, making it easier for clinicians to focus on what truly matters: providing quality care for their patients.

Glooko EHR Integrations

A Step Toward the Future of Diabetes Care

Following the COVID-19 pandemic, clinical teams who provide care to the more than 38 million people in the U.S. living with diabetes have greatly declined in number, furthering the urgent need for seamless, data-driven solutions to help reduce administrative burdens and workloads that drive burnout.

  • Since 2022, more than 138,000 nurses left the workforce due to stress, burnout, and retirement. New data from the NCSBN reveals almost 40% of nurses intend to leave the workforce by 2029, leaving the remaining time-pressed nurses to provide care to an already large patient population.
  • Based on a recent GoodRx study, more than 70% of U.S. counties don’t have an endocrinologist and the number of trained endocrinologists is declining, meaning primary care providers must be knowledgeable in diabetes management and shoulder the workload.
  • There is a significant shortfall of certified diabetes care and education specialists (CDCES), impacting diabetes care quality. In the U.S., there are about 19,500 diabetes educators — roughly 1 CDCES per 1,000 individuals with diabetes. An additional 35,000 educators would be required to meet the current demands of patients in the U.S. alone, furthering the workload burden.

And the burnout by clinicians and care teams is only going to grow greater as 98 million American adults have prediabetes, according to the CDC.

By optimizing and integrating with leading EHR systems, Glooko is taking a significant step forward in transforming diabetes management and reducing extra steps taken by healthcare providers to improve the quality of care. Our integrations help improve workflows, limit platform switching, simplify clinical decision-making, and support better outcomes for both healthcare providers and people with diabetes.

These integrations represent our ongoing commitment to delivering cutting-edge, interoperable solutions that empower both clinical teams and patients in making diabetes easier to manage.

Ready to Learn More?

Healthcare providers and hospital systems can access EHR integrations by reaching out to our dedicated team for a demo. With robust support from our dedicated team, some integrations, like with Epic, can be up and running within a weeks, making it easier than ever to take advantage of the benefits Glooko has to offer.

To learn more about Glooko’s many EHR integrations, visit our Integration Portal.

How Glooko is Transforming Diabetes Care: My First Six Months as CEO

Glooko's Mike Alvarez

Glooko CEO Mike AlvarezOver the past several months since stepping into the role of CEO at Glooko, I’ve been reflecting on the incredible progress we’ve made, and the immense opportunities that lie ahead. Each day has reaffirmed my belief that our mission to transform diabetes care is both urgent and achievable. I’m more energized than ever to guide Glooko toward a future where we deliver an even greater impact for people with diabetes and those who care for them.

When I think about the future of diabetes care, one word comes to mind: transformation. Across the globe, health systems, clinicians, and people living with diabetes are looking for a holistic approach, one that brings together cutting-edge technology, patient-centric insights, and secure, scalable solutions. At Glooko, we’ve made it our mission to deliver exactly that.

Our Vision: Transforming Diabetes Care

We believe in transforming diabetes care by making it simpler, more connected, and fundamentally centered on people with diabetes. This vision underpins every decision we make, whether we’re enhancing our platform’s EHR integration, partnering with global device manufacturers, or expanding our footprint in new markets.

Our Mission: Simplifying Care and Strengthening Connections

At Glooko, we say: “We simplify care, strengthen connections, and together create a brighter future for people living with diabetes, healthcare providers, and caregivers.”

Simplify Care

We hear time and again about fragmented workflows and siloed data, forcing providers and patients to juggle multiple device platforms (mobile and web), apps, and logins. Our platform intends to change this, meaning clinicians can potentially spend less time on administrative tasks and more time where they’re needed most: caring for patients and focused on improving outcomes.

Strengthen Connections

We also see the power of community and shared decision-making. Through Glooko, patients, caregivers, and healthcare teams can collaborate more effectively, share real-time data, and gain insights that drive meaningful change in care plans. We aim to reduce the cognitive burden of diabetes data and decision making.

In my view, these are the five biggest differentiators that make Glooko stand out:

  1. Patient First Mindset: Everything we do revolves around putting patients first. We collaborate closely with clinicians, caregivers, and people living with diabetes to ensure our technology meets real-world needs.
  2. Commitment to Quality and Security: From ISO 27001 to HiTrust and SOC 2 Type 2 certifications, our platform is backed by enterprise-grade security and rigorously tested reliability. We understand that healthcare data is precious and that trust is earned through quality.
  3. Innovation That Matters: Our platform is more than a “data upload tool.” It’s an engine designed to support clinical decision making. Whether it’s EHR interoperability or automated patient nudges, we constantly push boundaries to develop meaningful solutions that scale globally.
  4. High-Performance Culture: Within the company, we’re building a talented, global team that challenges the status quo. This energy fuels our drive to expand into new markets, partner with industry leaders, and improve access to diabetes care around the world.
  5. Better Together: Collaboration is in our DNA, and that includes partnerships with device manufacturers, healthcare providers and hospital systems. By joining forces with stakeholders across the healthcare ecosystem, we have the opportunity to create value that benefits everyone, especially people living with diabetes.

Scaling for the Future

Our work has already touched millions of lives, but we’re just getting started. With rising rates of diabetes worldwide, the need for an integrated, secure, and human-centered solution has never been greater. That’s why we’re investing in global expansion, forging new alliances, and refining our platform to make sense of the high volume of data in diabetes care.

Scaling effectively also means staying true to our roots. Our commitment to patient outcomes, uncompromising quality, and secure innovation will remain the bedrock of Glooko’s growth. As we continue to expand, our North Star will always be the same: transforming diabetes care on a global scale and making diabetes easier to manage for everyone in the diabetes care ecosystem.

A Commitment to People Living with Diabetes, Above All

Behind every data point or device upload is a person managing a complex, life-altering condition. We never lose sight of that human element. As Glooko grows, our Patients First value continues to guide us toward solutions that truly make a difference, reducing clinical burdens, improving outcomes, and helping people with diabetes live fuller, healthier lives.

MKT-0532 01

Making Diabetes Management Easier for All:
Glooko’s Renewed Vision for the Future

As I begin my new role as CEO of Glooko, I’m filled with both excitement and a deep sense of responsibility. Diabetes management has always been a deeply personal and complex journey for so many individuals, and the opportunity to lead a company dedicated to easing that burden is truly inspiring. This is more than just a new chapter for me; it’s a chance to make a real difference in the lives of people living with chronic conditions.

With the $100 million Series F financing, Glooko is in a strong position to accelerate our mission—simplifying diabetes management for patients, clinicians, and their care teams. As someone who has spent the majority of my career in healthcare technology and chronic condition management, I’m particularly excited to lead a company that is committed to easing the burden for patients with diabetes and their care teams. I’ve seen firsthand how data—while crucial—can become overwhelming, especially for those managing a condition like diabetes that requires constant monitoring. Whether it’s managing blood glucose levels, using insulin pumps, or trying to make sense of data from multiple apps, patients and clinicians are often left navigating a complex web of information. Particularly for physicians, sifting through and trying to make sense of that same sea of data to provide timely, effective care can be a daunting task.

At Glooko, we’re focused on tackling these challenges head-on. Our platform has the potential to provide actionable insights that streamline the management of chronic diseases like diabetes. We aim to simplify workflows, so that endocrinologists and diabetes care teams can focus on what matters most—to develop early intervention and care pathways that improve patient outcomes. We are also focused on expanding our work with our life sciences partners to enable clinical research and improve outcomes.

Our goal is clear: to make diabetes management easier for everyone—patients, clinicians, and partners. With the recent funding, we’re able to invest further in expanding our platform to support even more customers and to strengthen our integrations with electronic medical records (EMRs). This not only helps clinicians manage their workloads more effectively but also improves care coordination across the board.

I couldn’t be more excited to lead Glooko through this next phase of growth. We are at the forefront of changing how chronic diseases are managed by leveraging data to create new care pathways that make a real difference in patients’ lives. The possibilities for what we can achieve together are limitless, and I’m eager to work with our incredible team to bring these innovations to life.

This moment marks the beginning of an exciting journey, and I’m confident that, together, we’ll continue to set new standards for chronic condition management—making it easier, more efficient, and more effective for all.

Happy Holidays from Glooko!

Glooko Holiday Message 2022

​​Season’s Greetings!

​​As we reflect on the past year, I’d like to take a moment to sincerely thank you, our customers, partners, friends and families for your continued partnership and support. While changing external market dynamics continued to present new challenges and new opportunities – what did not change was our commitment to our mission. As we look ahead to 2023 we are excited to increase our impact and to take our solutions to the next level, pushing the envelope of digital health to deliver the strongest positive patient outcomes for people with chronic conditions. We have many things to be thankful for, and several exciting new initiatives to share with you in 2023.

​​Wishing you a very happy & healthy holiday, and we look forward to our continued partnership in the new year.

​​Warmest holiday greetings,

​​Russ Johannesson
Chief Executive Officer
Glooko

Academy™ for U.K. and Ireland Healthcare Providers Adds Module to Further Training on Connected Pens Used by People with Diabetes

Glooko Academy Connected Smart Diabetes Pens

This month, Academy™, a free educational platform Glooko developed in conjunction with the Association of British Clinical Diabetologists (ABCD)/Diabetes Technology Network UK (DTN-UK) and DigiBete, launched a new training module on connected pens used by people with diabetes. This marks the eighth module on the CPD accredited platform for healthcare professionals in the U.K and Ireland to improve their knowledge of diabetes technologies.

The new course educates healthcare professionals on the benefits of connected pens, the different types of smart insulin pens available and how the data generated by these pens can be used in clinical practice to support people with diabetes.

“Smart pens are another emerging tool that can help us get a more complete picture of what is causing the ups and downs that are so frustrating for people living with diabetes,” said Dr. Pratik Choudhary, professor of diabetes, Leicester Diabetes Centre, University of Leicester, UK and chair of DTN-UK. “We’re really pleased to launch the latest course in Academy™ to help support healthcare providers in making the best use of this technology.”

For people with diabetes, connected pens allow accurate and up-to-date recording of the timing and doses of insulin administration. Healthcare teams supporting patients using connected pens are able to gather a more complete picture of their patients’ diabetes therapy and can help understand causes of high or low blood glucose readings. This innovative connected pen technology combined with digital health platforms packed with data, like Glooko, can enable care teams to make informed decisions around insulin dosing for their patients.

“Connected pens are the latest exciting diabetes technology development, designed to enable integration of both glucose and insulin data to facilitate more detailed and informed discussions in the diabetes clinic,” said Dr. Emma Wilmot, consultant diabetologist, University Hospitals of Derby & Burton; founder, ABCD/DTN-UK; and honorary (clinical) associate professor, University of Nottingham.

Healthcare professionals in the U.K. and Ireland who are interested in advancing their knowledge of the latest diabetes technologies can register for Academy™ for free.

MKT-0349 01

Glooko Named a Leader by Independent Research Firm in Diabetes Digital Therapeutics for Healthcare Payers

Glooko Named a Leader in Diabetes Digital Therapeutics for Healthcare Payers

Glooko Named a Leader in Diabetes Digital Therapeutics for Healthcare Payers

At Glooko, we believe being named a leader in CB Insights’ Diabetes Digital Therapeutics For Healthcare Payers — Execution & Market Strength Positioning (ESP) Vendor Matrix validates what our customers have been saying about our commitment to providing innovative digital health tools for chronic conditions like diabetes.

Glooko was among the select companies that CB Insights invited to participate in its December 2021 ESP evaluation, Diabetes Digital Therapeutics For Healthcare Payers — ESP Vendor Matrix. In this evaluation, Glooko was cited as a leader in digital therapeutics for diabetes.

“It’s an honor to see Glooko named a leader in diabetes digital therapeutics,” said Russ Johnannesson, CEO of Glooko. “Our team works hard to ensure our connected care solutions help people with diabetes and related chronic conditions and their healthcare provider better manage their disease and improve health outcomes.”

With diabetes being a leading driver of medical costs globally, it is one of the most prevalent chronic conditions in the U.S. That’s why we’re committed to delivering innovative platforms to healthcare providers, care management teams and patients in the U.S.—and around the world—to improve management of chronic conditions.

Through our population-level stratification tools, consumer-facing insulin dosing algorithms and industry-leading number of published clinical trials and patents, we’re improving care for people with chronic conditions like diabetes through collaboration and innovation.

View and download CB Insights’ Diabetes Digital Therapeutics For Healthcare Payers — ESP Vendor Matrix

MKT-0341 01

Glooko Adds SOC 2 Type 1 Certification to its Growing Data Security and Privacy Accreditations

SOC 2 Type 1 Certification Glooko

At Glooko, we’re committed to the security of personal data and protected health information. Through certifications from key global organizations, we’ve established both privacy protection and data security as critical, high-priority parts of our processes, practices and culture.

We’re proud to announce that Glooko is now SOC 2 Type 1 certified. This comprehensive reporting standard established by the American Institute of Certified Public Accountants was verified through independent validation and attests that Glooko has all the required controls in place for its people, systems and processes to ensure the security of its customers’ data as well as the company’s own software.

“Adding SOC 2 Type 1 certification alongside our existing HITRUST CSF certification provides additional assurance to our current and prospective customers that we’re in compliance with leading industry standards and their data is safe,” said Greg Omundson, technical project manager at Glooko. “We couldn’t have achieved this certification without the hard work of Team Glooko and their ongoing commitment to the security and privacy of data from customers.”

Over the coming months, we’ll continue to work toward achieving certifications from other leading global security and privacy organizations.

Glooko’s Real-World Diabetes Patient Data Now Available on AWS Marketplace

AWS Marketplace Glooko

As of today, our real-world data repository at Glooko represents over five billion data points with 3.4 million users globally in over 7,500 clinics across 29 countries in 21 languages. The robust data points we gather that’s constantly growing each day include continuous blood glucose readings, insulin, exercise, food, medications, blood pressure, weight and patient demographics.

Our real-world data is currently being used in retrospective clinical research trials, which could potentially lead to breakthrough digital therapeutic solutions that better manage patients’ health.

And this month, Glooko joined the AWS Marketplace, Amazon’s digital catalog of commercial data products from category-leading data providers that enables individuals and companies to find, subscribe and use third-party data in the cloud.

Our leading digital health company’s de-identified patient data is now available to be applied across multiple use cases, including clinical trial design and recruitment, pre- and post-efficacy analysis of pharmaceutical interventions, population health studies and health economics and outcomes research (HEOR). Clinical researchers, data scientists and others in the life sciences space will be able to benefit greatly if they’re interested in:

  • Blood glucose statistics

  • Insulin statistics

  • Diabetes device utilization

  • Blood glucose and insulin-related statistics

  • Blood glucose readings

  • Demographics information

  • Biometrics information

  • Lifestyle data

These data points are collected by Glooko when our platform users upload and share their data in-clinic or through remote data collection tools, like the Glooko Research Mobile App, available on the App Store and Google Play Store, and the Glooko Research Uploader.

“There are so many beneficial uses of this data from patients with diabetes and related chronic conditions,” said Kevin Dougherty, vice president, life sciences at Glooko. “AWS Marketplace allows clinical researchers to easily access and utilize our existing datasets in their retrospective clinical trials to help better inform decision-making around device selection, post-marketing and HEOR.”

Some of the additional use cases for Glooko’s data include understanding how devices and wearables perform in a variety of typical practice settings and populations, as well as demonstrating the value of medicine and devices through evidence-based health economic evaluation and real-world outcomes for pricing, reimbursement and overall cost of a disease.

To access Glooko’s de-identified patient data, visit our AWS Marketplace listing and subscribe or email our team.

Glooko Release 21.4 Brings Localized Unit of Measurement, Additional Data and Expanded Device Compatibility

Glooko Release 21.4

At Glooko, we’re always innovating and expanding the features of our platform for people with diabetes and chronic conditions. Through user research, we’ve implemented a series of updates in Glooko Release 21.4 for professional and personal users.

“In this release, we wanted to ensure patients using our digital health platform were having a more seamless experience and healthcare providers could access more powerful analytics,” said Sebastian Dreijer, Glooko’s director of product management for EMEA. “By introducing a default localized unit of measurement feature and additional devices compatible with Glooko, we’re expanding our reach globally while adapting our features to meet the needs of local markets.”

To simplify Glooko account set-up for healthcare providers and patients, newly created accounts will now default to the local unit of measurement. Patients who register with Glooko directly will have their unit of measurement set to the default for their country of residence, while patients who have their account created in a clinic will have their unit of measurement set to the clinic’s defined unit of measure. These settings can also be adjusted in your Glooko account profile.

Glooko Tandem LGS PLGS

For healthcare providers, care teams and people with diabetes using Tandem Basal-IQ and Control-IQ, there is now additional data available, including a bi-hourly analysis detailing the percentage of LGS/PLGS suspended and the number of suspensions for each bihourly segment, as well as additional insulin information. The Overview graph for a 1-day time period will now detail the amount of scheduled basal insulin units and include the number of units for both bolus and basal insulin on the insulin pie chart.

Additionally, we have expanded Glooko’s device compatibility to include:

  • Ypsomed Mylife Cloud: It is now possible to connect a Mylife Cloud account to Glooko for wireless syncing

  • Abbott Freestyle Libre (Sweden/Norway Only): The Freestyle Libre can now be uploaded via both Transmitter and Glooko Uploader

  • Abbott Freestyle Libre 2 (Sweden/Norway Only): The Freestyle Libre 2 can now be uploaded via the Glooko Uploader

With the human body turning carbohydrates into glucose, blood sugar levels rise when you eat foods with carbohydrates. That’s why we’ve updated the Carb Display on the Overview graph on the Glooko Web App to make it easier to see manually entered carbs and device synced carbs within the Carbs section. Carb entries entered within 10 minutes of each other will now be grouped together and each carb entry is visible when hovering over the value on the graph.

Glooko Parental Guardian Consent

For patients using Glooko, account creation for minors in some regional jurisdictions now requires a parent or guardian email to be added during the registration process. Consent agreements will be sent to the parent or guardian email entered during registration. Once the parent or guardian reviews and accepts the consent and selects ‘Activate Account,’ the minor can access and utilize his or her Glooko account.

For the full release notes, click here.

Have a question for our customer support team? Visit the Help Center, or email [email protected] (North America) or [email protected] (Europe).

Join Glooko’s 2021 Wellness Challenge

Team Glooko’s 2021 Wellness Challenge

To further our commitment to our community of patients with diabetes, clinical researchers and healthcare providers, Glooko is holding a Wellness Challenge for Team Glooko October 4 to 10, 2021, and we want you to get involved.

Our Wellness Challenge, which leads up to the 30th anniversary of the American Diabetes Association’s virtual Tour de Cure on October 10, will provide you with daily wellness tips and encourage you to improve your health through the Glooko app.

We also invite you to join Team Glooko on the Tour de Cure. With your support and a $30,000 fundraising match from Glooko, we’ll help the ADA continue to provide community-based education programs, protect the rights of people with diabetes and fund critical research for a cure. If you’re interested, register and fundraise, or support our fundraising efforts by donating here.

October 4: Activate your Glooko App
Let’s start the Wellness Challenge by highlighting the importance of creating a comprehensive data picture, containing everything from your blood glucose readings to exercise activity. Begin by downloading and installing the Glooko app, available on the Google Play Store and App Store. After installing the app on your mobile device, create a Glooko account if you don’t already have one and then sync the Glooko app with compatible CGMs, blood glucose meters and fitness and health apps.

October 5: Track your Food Intake
Tracking food intake is vital when monitoring your health. Luckily, food intake can be tracked very easily with the Glooko app, where you can see how different foods affect blood glucose readings. For today’s challenge, we encourage you to add what you consume manually, via the barcode scanner or using voice capture to your Glooko app.

October 6: Track your Weight and Medications and Take the ADA’s Diabetes Risk Test
Did you know the Glooko mobile app can be used to track weight, blood pressure, A1c, exercise, insulin and medication? These lifestyle events can be viewed alongside glucose data to reveal trends and patterns, which can help healthcare providers uncover conditions like prediabetes. For today’s challenge, track your weight and medications in the Glooko app and take 60 seconds to complete the ADA’s Type-2 Diabetes Risk Test.

October 7: Set Reminders
Everyone has busy days which can make it hard to remember when to take medication or blood glucose readings. Luckily, you can set-up reminders within the Glooko app and you’ll be alerted to actions you need to take. For today’s challenge, set a reminder or two in your Glooko app.

October 8: Uncover Health Insights
Glooko’s web app can be used for monitoring your blood glucose readings, Bolus and Basal rates, nutrition and more. For today’s challenge, log in to the web app, see what insights you uncover and use the data to get better control of your health.

October 9: Track your Fitness and Get Active
Daily fitness activity is very important for your overall health, and the Glooko app makes it easy to track your steps and fitness data manually or with compatible third party vendors. For today’s challenge, we encourage you to take 10,000 steps or take part in 30 minutes of moderate activity. Once you’re done, check in the Glooko app how your exercise impacted your blood glucose readings.

October 10: Build Community and Support Tour de Cure
At Glooko, we’re dedicated to collaboration, which we use to develop and strengthen our relationships within the diabetes ecosystem and improve health outcomes of patients with diabetes. Every year, Glooko participates in the Tour de Cure, supporting the ADA’s efforts funding research to take steps closer to a cure and provide resources to healthcare professionals and over 34 million Americans living with diabetes. For today’s challenge, tune in to the live stream of the 30th Anniversary Tour de Cure, a program we proudly support, and share on social media how Glooko, and this week’s Wellness Challenge, has helped you improve your health.

We hope you’ve enjoyed our Wellness Challenge! Explore the Glooko app for more ways to help you track your health data and make more informed decisions about your health.